Agile Therapeutics was founded in 1997 on the principle that women want and need more convenient contraceptive options. Agile has a pipeline of contraceptive products in late-stage clinical development that represent significant near-term revenue potential. These contraceptives are transdermal patches based on a proprietary delivery technology developed by Agile. The company will compete in the more than $4 billion contraceptive market.

The Agile proprietary pipeline includes:

• AG200-15: a once-weekly, low-dose combination hormonal contraceptive
• AG890: a low-dose progestin-only contraceptive
• Additional contraceptive patch products ready to enter the clinic

The proprietary transdermal delivery technology developed by Agile, Skinfusion^®, results in a contraceptive patch that is soft and flexible with a silky feel. The Agile patch has demonstrated favorable wearability and adhesion in clinical trials.

Use of a contraceptive patch has been shown to increase compliance when compared to a daily oral regimen¹ and provides a convenient form of birth control for women.

Agile Therapeutics is headquartered in Princeton, NJ.

1 Archer D, et al. Assessment of compliance with a weekly contraceptive patch (Ortho EvraTM/EvraTM) among North American women. Fertil Steril 2002;77:S27-31.